Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas

被引:25
作者
Kehrer-Sawatzki, Hildegard [1 ]
Kluwe, Lan [2 ]
Friedrich, Reinhard E. [3 ]
Summerer, Anna [1 ]
Schaefer, Eleonora [1 ]
Wahllaender, Ute [4 ]
Matthies, Cordula [5 ]
Gugel, Isabel [6 ]
Farschtschi, Said [2 ]
Hagel, Christian [7 ]
Cooper, David N. [8 ]
Mautner, Victor-Felix [2 ]
机构
[1] Univ Ulm, Inst Human Genet, D-89081 Ulm, Germany
[2] Univ Hosp Hamburg Eppendorf, Dept Neurol, D-20246 Hamburg, Germany
[3] Univ Hosp Hamburg Eppendorf, Dept Oral & Maxillofacial Surg, D-20246 Hamburg, Germany
[4] KBO Children Clin Ctr Munich, D-81377 Munich, Germany
[5] Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany
[6] Univ Hosp Tubingen, Dept Neurosurg, D-72076 Tubingen, Germany
[7] Univ Hosp Hamburg Eppendorf, Dept Neuropathol, D-20246 Hamburg, Germany
[8] Cardiff Univ, Inst Med Genet, Sch Med, Cardiff CF14 4XN, S Glam, Wales
关键词
TUMOR-SUPPRESSOR GENE; UNILATERAL VESTIBULAR SCHWANNOMA; NEUROFIBROMATOSIS; PATIENTS; GERM-LINE MUTATIONS; FAMILIAL SCHWANNOMATOSIS; TYPE-2; SOMATIC MOSAICISM; SPORADIC SCHWANNOMATOSIS; DIAGNOSTIC-CRITERIA; LZTR1; MUTATION;
D O I
10.1007/s00439-018-1909-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Schwannomatosis and neurofibromatosis type 2 (NF2) are both characterized by the development of multiple schwannomas but represent different genetic entities. Whereas NF2 is caused by mutations of the NF2 gene, schwannomatosis is associated with germline mutations of SMARCB1 or LZTR1. Here, we studied 15 sporadic patients with multiple non-intradermal schwannomas, but lacking vestibular schwannomas and ophthalmological abnormalities, who fulfilled the clinical diagnostic criteria for schwannomatosis. None of them harboured germline NF2 or SMARCB1 mutations as determined by the analysis of blood samples but seven had germline LZTR1 variants predicted to be pathogenic. At least two independent schwannomas from each patient were subjected to NF2 mutation testing. In five of the 15 patients, identical somatic NF2 mutations were identified (33%). If only those patients without germline LZTR1 variants are considered (n = 8), three of them (37.5%) had mosaic NF2 as concluded from identical NF2 mutations identified in independent schwannomas from the same patient. These findings imply that a sizeable proportion of patients who fulfil the diagnostic criteria for schwannomatosis, are actually examples of mosaic NF2. Hence, the molecular characterization of tumours in patients with a clinical diagnosis of schwannomatosis is very important. Remarkably, two of the patients with germline LZTR1 variants also had identical NF2 mutations in independent schwannomas from each patient which renders differential diagnosis of LZTR1-associated schwannomatosis versus mosaic NF2 in these patients very difficult.
引用
收藏
页码:543 / 552
页数:10
相关论文
共 52 条
  • [1] A method and server for predicting damaging missense mutations
    Adzhubei, Ivan A.
    Schmidt, Steffen
    Peshkin, Leonid
    Ramensky, Vasily E.
    Gerasimova, Anna
    Bork, Peer
    Kondrashov, Alexey S.
    Sunyaev, Shamil R.
    [J]. NATURE METHODS, 2010, 7 (04) : 248 - 249
  • [2] Familial schwannomatosis with a germline mutation of SMARCB1 in Japan
    Asai, Katsunori
    Tani, Shoichi
    Mineharu, Yohei
    Tsurusaki, Yoshinori
    Imai, Yukihiro
    Agawa, Yuji
    Iwaki, Koichi
    Matsumoto, Naomichi
    Sakai, Nobuyuki
    [J]. BRAIN TUMOR PATHOLOGY, 2015, 32 (03) : 216 - 220
  • [3] The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene
    Baser, ME
    [J]. HUMAN MUTATION, 2006, 27 (04) : 297 - 306
  • [4] GERMLINE MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 TUMOR-SUPPRESSOR GENE
    BOURN, D
    CARTER, SA
    MASON, S
    EVANS, DGR
    STRACHAN, T
    [J]. HUMAN MOLECULAR GENETICS, 1994, 3 (05) : 813 - 816
  • [5] Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis
    Boyd, C.
    Smith, M. J.
    Kluwe, L.
    Balogh, A.
    MacCollin, M.
    Plotkin, S. R.
    [J]. CLINICAL GENETICS, 2008, 74 (04) : 358 - 366
  • [6] Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb
    Castellanos, Elisabeth
    Bielsa, Isabel
    Carrato, Cristina
    Rosas, Imma
    Solanes, Ares
    Hostalot, Cristina
    Amilibia, Emilio
    Prades, Jose
    Roca-Ribas, Francesc
    Lazaro, Conxi
    Blanco, Ignacio
    Serra, Eduard
    [J]. BMC MEDICAL GENOMICS, 2015, 8
  • [7] Human Splicing Finder: an online bioinformatics tool to predict splicing signals
    Desmet, Francois-Olivier
    Hamroun, Dalil
    Lalande, Marine
    Collod-Beroud, Gwenaelle
    Claustres, Mireille
    Beroud, Christophe
    [J]. NUCLEIC ACIDS RESEARCH, 2009, 37 (09)
  • [8] Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: A clinical and molecular study
    Evans, DGR
    Mason, S
    Huson, SM
    Ponder, M
    Harding, AE
    Strachan, T
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (04) : 361 - 366
  • [9] Somatic mosaicism: A common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis
    Evans, DGR
    Wallace, AJ
    Wu, CL
    Trueman, L
    Ramsden, RT
    Strachan, T
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (03) : 727 - 736
  • [10] Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations
    Evans, DGR
    Trueman, L
    Wallace, A
    Collins, S
    Strachan, T
    [J]. JOURNAL OF MEDICAL GENETICS, 1998, 35 (06) : 450 - 455